You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

615 Items
Cancer Type: Hematologic, Leukemia - Acute Myeloid (AML)     
Intent: Curative
May 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative, Palliative
May 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative, Palliative
May 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative, Palliative
May 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative, Palliative
May 2019
Cancer Type: Breast     
Intent: Palliative
Drugs Used:
abemaciclib (Unfunded)
Jun 2019
Cancer Type: Breast     
Intent: Palliative
Funding:
ODB Limited Use
    anastrozole - For the treatment of metastatic breast cancer in hormone receptor positive post-menopausal women
Drugs Used:
abemaciclib (Unfunded),
Jun 2019
Cancer Type: Breast     
Intent: Palliative
Drugs Used:
abemaciclib (Unfunded),
fulvestrant (Unfunded)
Jun 2019
Cancer Type: Breast     
Intent: Palliative
Funding:
ODB Limited Use
    letrozole - Treatment of metastatic breast cancer in hormone receptor positive postmenopausal women
Drugs Used:
abemaciclib (Unfunded),
Jun 2019
Cancer Type: Genitourinary, Prostate     
Intent: Palliative
Funding:
Exceptional Access Program
    abiraterone - Metastatic castrate-resistant prostate cancer, with specific criteria
ODB - General Benefit
    dexamethasone
May 2019
Cancer Type: Genitourinary, Prostate     
Intent: Palliative
Funding:
Exceptional Access Program
    abiraterone - Metastatic castrate-resistant prostate cancer, with specific criteria
ODB - General Benefit
    prednisone
May 2019
Cancer Type: Breast     
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
  • Paclitaxel - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
  • Paclitaxel - Neoadjuvant Treatment for Non-Metastatic Breast Cancer
New Drug Funding Program
  • Trastuzumab - Adjuvant Treatment for HER2_neu-Overexpressing Primary Breast Cancer
Evidence Building Program
  • Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
  • Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Supplemental
Jan 2019